Identification of beneficial populations for targeted-immunotherapy combinations: tailoring later-line care for patients with pMMR/MSS metastatic colorectal cancer
The study indicates that targeted-immunotherapy combination offers more benefits than targeted therapy alone for MSS mCRC in the third-line or beyond setting.
Authors
- Zhisong Fan
- Jing Han (ORCID: https://orcid.org/0000-0001-6490-2052)
- Feng Li (ORCID: https://orcid.org/0000-0002-9201-1668)
- Yudong Wang (ORCID: https://orcid.org/0000-0002-4708-6345)
- Dan Li (ORCID: https://orcid.org/0000-0002-2691-5175)
- Yan Liu (ORCID: https://orcid.org/0000-0001-6868-5454)
- Xue Zhang (ORCID: https://orcid.org/0000-0002-8179-138X)
- Long Wang (ORCID: https://orcid.org/0000-0002-3705-1763)
- Hui Jin (ORCID: https://orcid.org/0000-0002-3803-0745)
- Jing Zuo (ORCID: https://orcid.org/0000-0002-2318-5349)
- Jiayin Liu (ORCID: https://orcid.org/0000-0001-9237-0823)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.3389/fimmu.2024.1462346
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57